Aetna to Give Away iPhones
Health insurance giant Aetna will start to give away iPhones, iPads and Apple Watches as part of an experiment. But will people use them for health reasons?
Health and Healthcare
All Health and Healthcare Articles
Newest first · Page 195
Tabula Rasa Healthcare Updates Expected IPO Pricing
Tabula Rasa Healthcare intends to price more than 4 million shares in the range of $13 to $15 per share in an initial public offering valued up to $74 million.
Fulgent Genetics Announces Potential Pricing for IPO
Fulgent Genetics expects to offer more than 4 million shares in an expected price range of $12 to $14 per share in an initial public offering valued up to about $74 million.
Short Sellers Increase Bets in Major Biotechs
The September 15 short interest data have been compared with the previous report, and short interest moves were upward across most of these selected biotech stocks.
Major Pharma Continues to See Rising Tide in Short Interest
The September 15 short interest data have been compared with the previous figures, and for most of the selected pharmaceutical stocks, short interest has increased.
Pfizer Decides Against the Split
Pfizer shares traded down marginally Monday morning after the company announced that it will abandon its plan to split into two companies.
New Crohn’s Disease Drug Approved by FDA
A unit of Johnson & Johnson has announced that the FDA has approved its Stelara for the treatment of moderately to severely active Crohn's disease.
4 Biopharma Companies Moving on Monday Ahead of the Presidential Debate
24/7 Wall St. has picked out some of the major companies in the health care sector that are moving ahead of the first presidential debate and added in some color for each.
How Much Will Consumers Save on New Humira Biosimilar?
In a time when government wrangling about drug prices is more than commonplace, news of a biosimilar for the mega-blockbuster Humira being approved took the backseat to many other things.
6 Biotech and Biohealth Analyst Picks for 50% to 150% Upside
The week of September 23 brought numerous analyst upgrades and downgrades in the biotech and biohealth space.
Could Puma Biotech Double After This FDA Approval?
Puma Biotechnology posted strong gains over the course of this past week, which began with some positive news from the FDA and continued with a huge analyst call.
Endo Shuffles the Deck With New CEO Appointment
Shares of Endo International saw a handy gain in Friday’s session after the company named its new president and chief executive officer.
Why Key Analyst Sees Puma Biotech Practically Doubling
Puma Biotechnology Inc. (NYSE: PBYI) has made solid gains over the course of this week, starting with some positive news from the U.S. Food and Drug Administration (FDA), but now shares are being pushed…
Analyst Has 3 Biotech Stocks to Buy With Over 100% Upside Potential
The three biotech stocks featured here are rated Outperform at Wedbush and have at least 100% potential upside to the posted price targets.
How Sarepta Is Cashing In on Its FDA Homerun
Making the move for a secondary offering after a stock has jumped massively is one way for companies to literally cash in on their recent success.